This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Aliskiren (Rasilez) for hypertension

< Back

Aliskiren (Rasilez) for hypertension


Cardiovascular Disease and Vascular Surgery

December 2006

Aliskiren (Rasilez®) is the first in a new drug class of oral direct renin inhibitors. Renin inhibition inhibits the conversion of angiotensinogen to angiotensin I. This is the rate-limiting step in the production of angiotensin II, which is a key mediator of blood pressure, body fluid volume, and vascular remodeling. It is administered at either 150 mg or 300 mg orally once daily.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts